Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
World J Pediatr ; 16(3): 305-313, 2020 Jun.
Article in English | MEDLINE | ID: mdl-31912317

ABSTRACT

BACKGROUND: Hearing impairment is one of the most common birth defects in children. Universal newborn hearing screenings have been performed for 19 years in Guangdong province, China. A screening/diagnosis/intervention system has gradually been put in place. Over the past 10 years, a relatively complete data management system had been established. In the present study, an etiological analysis of newborn cases that failed the initial and follow-up screenings was performed. METHODS: The nature and degree of hearing impairment in newborns were confirmed by a set of procedures performed at the time of initial hearing screening, rescreening and final hearing diagnosis. Then, multiple examinations were performed to explore the associated etiology. RESULTS: Over a period of 10 years, 720 children were diagnosed with newborn hearing loss. Among these children, 445 (61.81%) children had a clearly identified cause, which included genetic factor(s) (30.56%), secretory otitis media (13.30%), maternal rubella virus infection during pregnancy (5.83%), inner ear malformations (4.86%), maternal human cytomegalovirus infection during pregnancy (2.92%), malformation of the middle ear ossicular chain (2.50%) and auditory neuropathy (1.81%). In addition, 275 cases of sensorineural hearing loss of unknown etiology accounted for 38.19% of the children surveyed. CONCLUSIONS: Long-term follow-up is needed to detect delayed hearing impairment and auditory development in children. The need for long-term follow-up should be taken into account when designing an intervention strategy. Furthermore, the use of the deafness gene chip should further elucidate the etiology of neonatal hearing impairment.


Subject(s)
Hearing Loss/congenital , Hearing Loss/etiology , Neonatal Screening , China/epidemiology , Disease Progression , Female , Follow-Up Studies , Hearing Loss/epidemiology , Humans , Infant, Newborn , Male , Retrospective Studies
2.
Eur Arch Otorhinolaryngol ; 276(10): 2715-2720, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31197531

ABSTRACT

PURPOSE: To investigate the long-term clinical effect of balloon dilation eustachian tuboplasty (BET) combined with tympanic tube insertion (TTI) in the treatment of chronic recurrent secretory otitis media (CRSOM). MATERIALS AND METHODS: A retrospective study of 30 cases of CRSOM treated with BET combined with TTI under general anesthesia between August 2014 and September 2016. Thirty cases of CRSOM treated with TTI in the same period were taken as the control group. All cases were followed over 24 months. The scores of eustachian tube (ET) function preoperation, 1 month, 6 months, 12 months, and 24 months postoperation were collected and analyzed, respectively. A satisfaction questionnaire was used to evaluate the therapy at 24-months postoperation. RESULTS: The symptoms were significantly improved and the ET score was obviously increased postsurgery in most cases treated with BET plus TTI compared with those treated with TTI alone. The highest ET score was obtained at 6 months post BET. Five (14%) cases (6 ears) of CRSOM recurred. The 24-month postoperation follow-up questionnaire showed that 84.6% of the patients were satisfied with the treatment, while ten cases (25%) in the TTI group recurred. CONCLUSION: BET combined with TTI surgery is an effective therapy for patients with CRSOM.


Subject(s)
Eustachian Tube/surgery , Otitis Media with Effusion , Tympanoplasty , Adult , Chronic Disease , Dilatation , Female , Humans , Male , Middle Aged , Middle Ear Ventilation/methods , Otitis Media with Effusion/diagnosis , Otitis Media with Effusion/surgery , Retrospective Studies , Secondary Prevention/instrumentation , Secondary Prevention/methods , Treatment Outcome , Tympanoplasty/instrumentation , Tympanoplasty/methods
3.
J Otol ; 10(4): 159-162, 2015 Dec.
Article in English | MEDLINE | ID: mdl-29937801

ABSTRACT

OBJECTIVE: To report a case of intractable skin reactions caused by bone-anchored hearing aid (BAHA) implantation to improve our understanding and treatment of BAHA implantation-caused skin reactions. METHODS: We reported a case of severe skin reactions caused by BAHA implantation. Related literature were also reviewed. RESULTS: We found grade IV skin reactions, including hyperplasia around the implant, which led to the removal of the BAHA implant 10 months after implantation. The findings indicated poor skin hygiene, allergy to titanium and inadequate surgicals skills as the possible causes of the skin reaction. CONCLUSION: Skin adverse reactions, usually rare in BAHA implantation patients, may cause implant removal and implantation failure. We suggest to further investigate the mechanisms underlying titanium allergy.

5.
Chin J Cancer ; 29(9): 824-9, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20800025

ABSTRACT

BACKGROUND AND OBJECTIVE: Radiation usually results in paranasal sinusitis in patients with nasopharyngeal carcinoma (NPC), which influences patients' quality of life. This study aimed to determine the relationships between dose distribution in the nasal cavity and nasal mucous injury in patients with NPC treated by intensity-modulated radiation therapy (IMRT), and to find the tolerable radiation dose for the nasal mucous. METHODS: Sixty-six patients with NPC treated by IMRT between October 2006 and November 2008 were enrolled. The irradiation dose in the nasal cavity was determined by the computer with the IMRT work platform. Mucociliary transport rate (MTR) was detected by modified saccharine test before IMRT, at the end of IMRT, and at 3, 6, and 12 months after IMRT. RESULTS: The data were available for 129 nasal cavities. The cavities receiving a mean dose below or equal to 37 Gy showed substantial preservation of nasal mucous after IMRT. The MRT decreased to (62.82 ± 38.59)%, (56.78 ± 37.79)%, (64.05 ± 39.37)%, and (71.13 ± 39.55)% of pre-IMRT value at 4 time points after IMRT, with significant differences among the data (P < 0.05). In contrast, when the cavities received a mean dose higher than 37 Gy, no significant differences in MTR among the time points were observed. At 3 months after IMRT, the MTR was the lowest (38.27% of pre-RT value). CONCLUSIONS: A mean radiation dose of ≤ 37 Gy for the nasal cavity is an optimal dose to protect the nasal cavity function.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Mucociliary Clearance/radiation effects , Nasopharyngeal Neoplasms/radiotherapy , Radiotherapy Dosage , Radiotherapy, Intensity-Modulated , Adult , Carcinoma, Squamous Cell/physiopathology , Female , Humans , Male , Nasal Cavity/radiation effects , Nasopharyngeal Neoplasms/physiopathology , Quality Control
SELECTION OF CITATIONS
SEARCH DETAIL